Literature DB >> 19062167

Comparison of chronic analgesic drugs prevalence in Parkinson's disease, other chronic diseases and the general population.

Christine Brefel-Courbon1, Sabrina Grolleau, Claire Thalamas, Robert Bourrel, Valérie Allaria-Lapierre, Robert Loï, Joelle Micallef-Roll, Maryse Lapeyre-Mestre.   

Abstract

Patients with Parkinson's disease (PD) frequently experienced pain. Nevertheless, there are no epidemiological data about frequency of pain in PD. We compare pain prevalence using analgesic prescription in PD patients, in the general population and in two samples of painful patients: diabetics and osteoarthritis patients in France. Data were obtained from the French System of Health Insurance for the year 2005. Medications (antiparkinsonian, antidiabetics drugs and osteoarthritis drugs) were used for identification of PD, diabetic and osteoarthritis patients. We estimated the prevalence of analgesic drugs prescription (at least one analgesic drug) and the prevalence of chronic analgesic drugs prescription (more than 90 DDD of analgesic drug). The study included 11,466 PD patients. PD patients significantly received more prescription of analgesics than the general population (82% versus 77%,) and fewer than patients with osteoarthritis (82% versus 90%). No significant difference was found between PD and diabetic patients. The chronic prescription of analgesic drugs was more prevalent in PD patients (33%) than in the general population (20%) and in diabetic patients (26%) and similar to that in osteoarthritis patients. PD patients were more exposed than the general population and diabetics to opiates, acetaminophen, and adjuvant analgesics chronic use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19062167     DOI: 10.1016/j.pain.2008.04.026

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  8 in total

Review 1.  Neurological diseases and pain.

Authors:  David Borsook
Journal:  Brain       Date:  2011-11-08       Impact factor: 13.501

2.  Dopaminergic denervation using [123I]-FPCIT and pain in Parkinson's disease: a correlation study.

Authors:  Estelle Dellapina; Jean Pellaprat; Djilali Adel; Jerome Llido; Estelle Harroch; Jean Baptiste Martini; Aurélie Kas; Anne Sophie Salabert; Fabienne Ory-Magne; Pierre Payoux; Christine Brefel-Courbon
Journal:  J Neural Transm (Vienna)       Date:  2019-01-31       Impact factor: 3.575

3.  Persistent use of analgesic medications in mild-to-moderate Alzheimer's disease.

Authors:  Adeline Gallini; Virginie Gardette; Bruno Vellas; Maryse Lapeyre-Mestre; Sandrine Andrieu; Christine Brefel-Courbon
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

4.  Laboratory monitoring of patients treated with antihypertensive drugs and newly exposed to non steroidal anti-inflammatory drugs: a cohort study.

Authors:  Jean-Pascal Fournier; Maryse Lapeyre-Mestre; Agnès Sommet; Julie Dupouy; Jean-Christophe Poutrain; Jean-Louis Montastruc
Journal:  PLoS One       Date:  2012-03-27       Impact factor: 3.240

5.  Effects of tapentadol on pain, motor symptoms and cognitive functions in Parkinson's disease.

Authors:  Ulderico Freo; Maurizio Furnari; Carlo Ori
Journal:  J Pain Res       Date:  2018-09-13       Impact factor: 3.133

Review 6.  Tapentadol for neuropathic pain: a review of clinical studies.

Authors:  Ulderico Freo; Patrizia Romualdi; Hans G Kress
Journal:  J Pain Res       Date:  2019-05-16       Impact factor: 3.133

7.  Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain.

Authors:  Carlo Cattaneo; Jaime Kulisevsky; Viviana Tubazio; Paola Castellani
Journal:  Adv Ther       Date:  2018-03-14       Impact factor: 3.845

8.  Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer disease and Parkinson disease.

Authors:  Timothy Lawn; Yahyah Aman; Katarina Rukavina; George Sideris-Lampretsas; Matthew Howard; Clive Ballard; Kallol Ray Chaudhuri; Marzia Malcangio
Journal:  Pain       Date:  2021-04-01       Impact factor: 7.926

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.